Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: report of one case and review of literature
10.3760/cma.j.issn.1009-9921.2018.04.009
- VernacularTitle: 异基因造血干细胞移植后自身免疫性溶血性贫血一例并文献复习
- Author:
Chao WANG
1
;
Shengli XUE
1
;
Zheng LI
1
;
Xiebing BAO
1
;
Xiaoling CHU
1
;
Rong HAN
1
;
Tao TAO
2
;
Depei WU
1
Author Information
1. Department of Hematology, the First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis, Ministry of Health, Collaborative Innovation Center of Hematology, Suzhou 215006, China
2. Department of Hematology, Xinghai Branch of the First Affiliated Hospital of Soochow University, Suzhou 215000, China
- Publication Type:Journal Article
- Keywords:
Hematopoietic stem cell transplantation;
Anemia, hemolytic, autoimmune;
Diagnosis;
Treatment outcome
- From:
Journal of Leukemia & Lymphoma
2018;27(4):228-233,237
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To summarize the clinical characteristics and treatment experiences of autoimmune hemolytic anemia (AIHA) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Methods:The clinical data of the patient with AIHA after allogeneic HSCT in Hematology Department of the First Affiliated Hospital of Soochow University was analyzed, and the literatures were reviewed.
Results:After receiving 2 years of allo-HSCT, one young male patient with severe aplastic anemia showed AIHA in the absence of obvious incentives. The patient healed with the treatments of glucocorticoid, intravenous injection of gamma globulin, plasma exchange combined with injection of CD20 monoclonal antibody. Through the literature review, it showed that AIHA patients after HSCT had a good response to regimens containing rituximab, while adult and malignant patients with post-HSCT AIHA had a higher mortality. Poor response to rituximab was one of the greatest risk factors for poor prognosis.
Conclusion:AIHA is not sensitive to hormone with a low treatment response, which is a risk factor for the increased mortality of allo-HSCT patients.
